• Investing
  • Stock
BigMoneyHall.com – Investing and Stock News
  • Economy
  • Editor’s Pick
Investing

Cancer drug sales help Johnson & Johnson withstand the hit from a stronger dollar

by July 24, 2022
by July 24, 2022

Johnson & Johnson (NYSE: JNJ) recorded quarterly results that surpassed financial analyst estimates in large part because of the strength of its pharmaceutical department, even as it cut its annual adjusted forecast because of a stronger dollar.

Johnson & Johnson joins other major multinationals in the United States, including IBM and Microsoft, warning of a hit from the United States currency’s current strength. This year through to July the U.S dollar has risen 12% and analysts expect it to stay strong for about the next 90 days.

Business highlights 

The company’s pharmaceutical department, Johnson & Johnson’s biggest unit, has recorded strong financial results in the last couple of quarters, even with delayed surgical processes negatively impacting sales growth at its medical devices department during the COVID pandemic.

Double-digit sales growth of the company’s cancer drug Darzalex and Stelara, its Crohn’s disease drug, helped Johnson & Johnson beat analyst estimates for Q2 profit. The company recorded total sales of about $24.02 billion representing a 3% increase, with almost half coming from outside the country. According to Refinitiv’s IBES data, analysts expected the company to record $23.77 billion in sales.

On an adjusted basis, Johnson & Johnson earned around $2.59 per share, surpassing the $2.54 per share analyst estimate. Stelara drug sales came to about $2.60 billion representing a 14.3% increase, while Darzalex revenue was around $1.99 billion, representing a staggering 40% increase.

The company’s COVID-19 vaccine, which is currently experiencing a slow uptake and weak demand, brought in revenue of $544 million in the quarter. J&J shares rose to $175.85 representing an increase of almost 1% in premarket trading.

How did management feel?

Joseph Wolk, the company’s Chief Finance Officer, in an interview with CNBC blamed the forecast drop wholly on the fluctuations of the U.S currency, pointing to the difference between the euro and the dollar.

The company now expects an adjusted full-year profit of $10.10 per share from a flat $10, compared to the prior $10.35 per share from $10.15.  

The post Cancer drug sales help Johnson & Johnson withstand the hit from a stronger dollar appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Biogen tops Q2 2022 earnings and revenue estimates
next post
General Electric unveils the names of its three future public companies

Related Posts

Nikkei 225 bullish momentum continues as the USD/JPY...

August 18, 2022

Brace for a retest of June lows: Lisa...

August 18, 2022

Apple shares are on their way to $200:...

August 17, 2022

Cisco Q4 earnings: ‘its real challenge is market...

August 17, 2022

Canadian firm writes off $150M Celsius bet

August 17, 2022

Jim Cramer on Sempra Energy stock: ‘I would...

August 17, 2022

BHP breakout, 50-MA support, and strong fundamentals pushing...

August 17, 2022

Genesis CEO steps down as crypto broker slashes...

August 17, 2022

U.K. inflation tops 10%: ‘the worst is yet...

August 17, 2022

Target stock is a ‘buy’ after lower-than-expected Q2...

August 17, 2022
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • Nikkei 225 bullish momentum continues as the USD/JPY rebounds

    August 18, 2022
  • Brace for a retest of June lows: Lisa Shalett

    August 18, 2022
  • Apple shares are on their way to $200: Credit Suisse

    August 17, 2022
  • Cisco Q4 earnings: ‘its real challenge is market share loss’

    August 17, 2022
  • Canadian firm writes off $150M Celsius bet

    August 17, 2022
  • Jim Cramer on Sempra Energy stock: ‘I would buy that’

    August 17, 2022

Editors’ Picks

  • 1

    Lessons From Penny Stock Legend Tim Grittani, the $13 Million Man!

    July 21, 2022
  • 2

    Exxon stock outlook: Piper Sandler sees a 25% upside

    July 20, 2022
  • 3

    Tesla Inc is on a ‘knife’s edge’ heading into the Q2 report: Analyst

    July 20, 2022
  • 4

    Wise share price popped after earnings. Is it a good buy?

    July 19, 2022
  • 5

    Scaling Up Tips From A 24-Year Old Millionaire Trader {VIDEO}

    July 24, 2022
  • 6

    Single-Family Home Construction Retreat Continued in June

    July 19, 2022
  • 7

    My Trigger to Enter $VAPR

    July 25, 2022

Categories

  • Economy (106)
  • Editor's Pick (34)
  • Investing (281)
  • Stock (16)

Latest News

  • Biden Borrows the Nixon Playbook on Recessions

    August 1, 2022
  • Raytheon maintains a decline on a descending triangle – What next?

    July 27, 2022
  • Multi-Millionaire Trader Explains Why You Should Start Trading With A Small Account {VIDEO}

    July 31, 2022

Investing News

  • Making the Case for IoT in Telehealth

    July 26, 2022
  • How To Trade Influencer Stocks {VIDEO}

    July 26, 2022
  • Should you buy Home Depot stock after solid Q2 results?

    August 16, 2022
  • About Us
  • Contacts
  • Email Whitelisting
  • Privacy Policy
  • Terms and Conditions

Disclaimer: BigMoneyHall.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 BigMoneyHall.com. All Rights Reserved.

BigMoneyHall.com – Investing and Stock News
  • Investing
  • Stock
BigMoneyHall.com – Investing and Stock News
  • Economy
  • Editor’s Pick
BigMoneyHall.com – Investing and Stock News
  • Investing
  • Stock
BigMoneyHall.com – Investing and Stock News
  • Economy
  • Editor’s Pick

Disclaimer: BigMoneyHall.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 BigMoneyHall.com. All Rights Reserved.

Read alsox

PayPal stock down 55% just attracted an...

July 27, 2022

Michael Burry is now long this one...

August 16, 2022

Palantir shares opened 15% down on Monday:...

August 8, 2022